CHMP Favors EU Approval of Ofev to Preserve Lung Function in SSc-ILD
The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Ofev (nintedanib) to preserve lung function in people with systemic sclerosis (SSc)-associated interstitial lung disease (SSc-ILD) in the European Union. Boehringer Ingelheim, the company marketing Ofev, submitted the request for this indication in…